Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue		$ 996	$ 791	$ 2,985	$ 1,403
Operating expenses:
Cost of revenue		1,381	1,779	4,792	4,809
Sales and marketing		2,920	4,016	11,472	12,893
General and administrative		6,649	6,858	20,337	23,916
Amortization of acquired intangible assets		82	505	559	1,516
Research and development		1,542	3,161	5,125	10,681
Total operating expenses		12,574	16,319	42,285	53,815
Operating loss		(11,578)	(15,528)	(39,300)	(52,412)
Other income (expense):
Interest income		70	124	252	408
Interest expense		(12)	(159)	(38)	(570)
Gain on deconsolidation of subsidiary		72,287		72,287
Change in fair value - equity method investment		407		407
Change in fair value - Senior Secured Convertible Notes		240	(4,392)	(2,488)	(5,772)
Loss on issue and offering costs - Senior Secured Convertible Note					(1,186)
Debt extinguishments loss - Senior Secured Convertible Notes		(1,403)	(1,764)	(2,535)	(3,032)
Debt modification expense				(2,000)
Change in fair value - derivative liability			(31)		(291)
Management fee income		700		700
Gain on sale of intellectual property					1,000
Other income (expense), net		72,289	(6,222)	66,585	(9,443)
Income (loss) before provision for income tax		60,711	(21,750)	27,285	(61,855)
Provision for income taxes
Net income (loss) before noncontrolling interests		60,711	(21,750)	27,285	(61,855)
Net loss attributable to the noncontrolling interests		3,688	4,079	11,075	11,716
Net income (loss) attributable to PAVmed Inc.		64,399	(17,671)	38,360	(50,139)
Less: Series B Convertible Preferred Stock dividends earned		(83)	(77)	(244)	(226)
Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests				(7,496)
Net income (loss) attributable to PAVmed Inc. common stockholders		$ 64,316	$ (17,748)	$ 30,620	$ (50,365)
Per share information:
Net income (loss) per share attributable to PAVmed Inc. common stockholders – basic	[1]	$ 6.43	$ (2.38)	$ 3.30	$ (7.23)
Net income (loss) per share attributable to PAVmed Inc. common stockholders – diluted	[1]	$ 1.44	$ (2.38)	$ 0.79	$ (7.23)
Weighted average common shares outstanding, basic		10,005,379	7,462,751	9,286,999	6,967,764
Weighted average common shares outstanding, diluted		44,475,638	7,462,751	43,069,449	6,967,764

[1] - Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net income (loss) per share calculation for the periods indicated.